CA2650711A1 - Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase - Google Patents
Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase Download PDFInfo
- Publication number
- CA2650711A1 CA2650711A1 CA002650711A CA2650711A CA2650711A1 CA 2650711 A1 CA2650711 A1 CA 2650711A1 CA 002650711 A CA002650711 A CA 002650711A CA 2650711 A CA2650711 A CA 2650711A CA 2650711 A1 CA2650711 A1 CA 2650711A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cholinesterase inhibitor
- substituted
- pyridazine compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79634806P | 2006-04-28 | 2006-04-28 | |
US60/796,348 | 2006-04-28 | ||
PCT/US2007/010463 WO2007127474A2 (fr) | 2006-04-28 | 2007-04-27 | Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2650711A1 true CA2650711A1 (fr) | 2007-11-08 |
Family
ID=38543765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002650711A Abandoned CA2650711A1 (fr) | 2006-04-28 | 2007-04-27 | Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase |
Country Status (4)
Country | Link |
---|---|
US (2) | US8158627B2 (fr) |
EP (1) | EP2015750A2 (fr) |
CA (1) | CA2650711A1 (fr) |
WO (1) | WO2007127474A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011156901A2 (fr) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Composés, compositions et procédés pour traiter la sclérose en plaques |
US8367672B2 (en) | 2004-11-02 | 2013-02-05 | Universite De Strasbourg | Pyridazine compounds, compositions and methods |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2264014A1 (fr) | 2001-08-31 | 2010-12-22 | Université Louis Pasteur | Pyridazines substitués comme anti-inflammatoirs et inhibiteurs de la protéine kinase |
US8105580B2 (en) | 2001-12-07 | 2012-01-31 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to promote wound healing |
US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
WO2006050359A2 (fr) | 2004-11-02 | 2006-05-11 | Northwestern University | Composes pyridazine et methodes |
EP2591784B1 (fr) | 2005-05-10 | 2016-09-14 | Intermune, Inc. | Dérives de la Pyridin-2-one comme modulateur du système de proteine kinase activé par le stress |
WO2007127375A2 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations contenant un composé de pyridazine |
WO2007127475A2 (fr) * | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur |
CA2650711A1 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase |
CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
WO2010021993A1 (fr) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne |
US20100227793A1 (en) * | 2009-03-04 | 2010-09-09 | Scott Thomas Brady | Compositions and Methods for Treating Amyotrophic Lateral Sclerosis |
CN109662964A (zh) | 2010-02-09 | 2019-04-23 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
WO2012064923A2 (fr) * | 2010-11-10 | 2012-05-18 | Purdue Research Foundation | Composés et procédés pour traiter la sclérose en plaques |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
WO2014144801A1 (fr) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Procédés et compositions pour améliorer la fonction cognitive |
EP3842424A1 (fr) | 2013-03-15 | 2021-06-30 | The Trustees of Columbia University in the City of New York | Modulateurs de map kinase et leurs utilisations dans le traitement de tauopathies |
EP3827820A1 (fr) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam pour améliorer la fonction cognitive |
WO2015120388A1 (fr) * | 2014-02-10 | 2015-08-13 | Cytori Therapeutics, Inc. | Thérapie cellulaire régénérative pour troubles du système nerveux central (snc) et espt |
CA2943363A1 (fr) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Pyridinones anti-fibrotiques |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
US20220048913A1 (en) * | 2017-07-12 | 2022-02-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
EP3697781B1 (fr) | 2017-10-17 | 2023-06-07 | Vanderbilt University | Antagonistes du récepteur muscarinique de l'acétylcholine m4 |
WO2019126559A1 (fr) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonistes du récepteur muscarinique de l'acétylcholine m4 |
TW202204323A (zh) * | 2020-03-27 | 2022-02-01 | 日商安斯泰來製藥股份有限公司 | 經取代之嗒𠯤化合物 |
WO2023163951A1 (fr) * | 2022-02-23 | 2023-08-31 | Immunochem Therapeutics, Llc | Traitement de l'hémorragie intracrânienne |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US39000A (en) * | 1863-06-23 | Improved paint composition | ||
NL92451C (fr) * | 1955-08-19 | |||
US3464988A (en) * | 1968-01-11 | 1969-09-02 | Bristol Myers Co | 3-hydrazinobenzo(h)cinnolines and 3 - hydrazinobenzocyclohepta-(5,6-c)pyridazines |
GB1345880A (en) | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
FR2510998B1 (fr) | 1981-08-07 | 1986-01-10 | Sanofi Sa | Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent |
FR2511366A1 (fr) * | 1981-08-11 | 1983-02-18 | Sanofi Sa | Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent |
DE3217325A1 (de) | 1982-05-08 | 1983-11-10 | Hoechst Ag, 6230 Frankfurt | 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung |
FR2540113A1 (fr) * | 1983-01-27 | 1984-08-03 | Sanofi Sa | Acides derives de la pyridazine actifs sur le systeme nerveux central |
US4562196A (en) * | 1984-04-06 | 1985-12-31 | Nelson Research & Development | 2,4-Diaminopyridine as a pharmacologic agent |
US4835275A (en) * | 1984-10-25 | 1989-05-30 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds |
US4754050A (en) * | 1984-10-25 | 1988-06-28 | Hoechst-Roussel Pharmaceuticals, Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
ATE63903T1 (de) * | 1984-10-25 | 1991-06-15 | Hoechst Roussel Pharma | 9-amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte verbindungen, verfahren zu ihrer herstellung und verwendung als arzneimittel. |
US4631286A (en) * | 1984-10-25 | 1986-12-23 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
AU578496B2 (en) * | 1984-11-01 | 1988-10-27 | Smith Kline & French Laboratories Limited | Tricyclic heterocyclic compounds |
IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
JPH0650381B2 (ja) | 1985-08-05 | 1994-06-29 | 富士写真フイルム株式会社 | ハロゲン化銀カラ−感光材料の処理方法 |
US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
FR2601011B1 (fr) * | 1986-07-03 | 1988-10-28 | Sanofi Sa | Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant |
US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
JP2531678B2 (ja) | 1987-05-27 | 1996-09-04 | 吉富製薬株式会社 | トリアゾロピリダジン誘導体 |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
DE3882982T2 (de) * | 1987-11-02 | 1993-11-25 | Yoshitomi Pharmaceutical | Kondensierte pyridazin-verbindungen und deren verwendung als arzneimittel. |
PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
US5693668A (en) * | 1989-06-22 | 1997-12-02 | Merrell Pharmaceuticals Inc. | Acetylcholinesterase inhibitors |
JP3075566B2 (ja) | 1990-05-15 | 2000-08-14 | エーザイ株式会社 | 光学活性インダノン誘導体 |
JP2965675B2 (ja) | 1990-11-21 | 1999-10-18 | エーザイ株式会社 | (―)―1―ベンジル―4―〔(5,6―ジメトキシ―1―インダノン)―2―イル〕メチルピペリジンの製造方法 |
US5104880A (en) * | 1991-05-01 | 1992-04-14 | Mayo Foundation For Medical Education And Research | Huperzine a analogs as acetylcholinesterase inhibitors |
JP3424180B2 (ja) * | 1993-02-23 | 2003-07-07 | 独立行政法人物質・材料研究機構 | P型熱発電材料 |
DE69408598T2 (de) | 1993-06-08 | 1998-09-17 | Vertex Pharmaceuticals Inc Cam | Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren |
US5554780A (en) * | 1994-05-05 | 1996-09-10 | Merrell Pharmaceuticals Inc. | Process for the preparation of 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives |
CN1125725A (zh) * | 1994-12-28 | 1996-07-03 | 中国科学院上海药物研究所 | 一类海克林碱衍生物及它的用途 |
EP0749972A1 (fr) * | 1995-06-21 | 1996-12-27 | Merrell Pharmaceuticals Inc. | Procédé de préparation de dérivées de 1-(3-trialkylsilylphényl)-2,2,2-trifluorométhyléthanone |
EP0971713B1 (fr) | 1997-03-03 | 2003-05-28 | Eisai Co., Ltd. | Utilisation d'inhibiteurs de la cholinesterase pour traiter des troubles de l'attention |
GB9707693D0 (en) | 1997-04-16 | 1997-06-04 | Smithkline Beecham Plc | Novel method of treatment |
TWI241295B (en) * | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003014110A1 (fr) * | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Derive de benzazepine, son procede de preparation et d'utilisation |
EP2264014A1 (fr) | 2001-08-31 | 2010-12-22 | Université Louis Pasteur | Pyridazines substitués comme anti-inflammatoirs et inhibiteurs de la protéine kinase |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
JP4021670B2 (ja) * | 2002-01-22 | 2007-12-12 | 株式会社東芝 | 半導体集積回路 |
JP2004096485A (ja) * | 2002-08-30 | 2004-03-25 | Sharp Corp | 電話制御システム |
FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
US20050072713A1 (en) * | 2002-11-19 | 2005-04-07 | Roger Wozniacki | Spacer for material handling industry and method and assembly for forming same |
PL377777A1 (pl) | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
FR2848452B1 (fr) | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
DK1651615T3 (da) * | 2003-07-29 | 2010-05-25 | High Point Pharmaceuticals Llc | Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander |
TW200528455A (en) * | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
AU2004309365A1 (en) * | 2003-12-19 | 2005-07-14 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7220858B2 (en) * | 2003-12-23 | 2007-05-22 | Barbeau Pharma, Inc. | Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
WO2006050359A2 (fr) | 2004-11-02 | 2006-05-11 | Northwestern University | Composes pyridazine et methodes |
AU2005302225B2 (en) * | 2004-11-02 | 2012-05-24 | Centre National De La Recherche Scientifique | Pyridazine compounds, compositions and methods |
JP2010500050A (ja) | 2006-04-27 | 2010-01-07 | シェノイ,ナルマダ,アール. | 身体通路の疾病を治療又は予防する組成物及び方法 |
WO2007130383A2 (fr) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions et traitements utilisant des pyridazines et des secrétases |
US20100168120A1 (en) | 2006-04-28 | 2010-07-01 | Neuromedix Inc. | Salts of pyridazine compounds |
WO2007127375A2 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations contenant un composé de pyridazine |
CA2650711A1 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase |
WO2007127475A2 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur |
US7732445B2 (en) * | 2006-07-21 | 2010-06-08 | Northwestern University | Myosin light chain kinase inhibitor compounds, compostions and related methods of use |
EP2131839A2 (fr) | 2007-03-02 | 2009-12-16 | Northwestern University | Compositions et traitements pour des troubles liés à des crises |
-
2007
- 2007-04-27 CA CA002650711A patent/CA2650711A1/fr not_active Abandoned
- 2007-04-27 US US12/298,623 patent/US8158627B2/en active Active
- 2007-04-27 WO PCT/US2007/010463 patent/WO2007127474A2/fr active Application Filing
- 2007-04-27 EP EP07756162A patent/EP2015750A2/fr not_active Withdrawn
-
2012
- 2012-02-17 US US13/399,079 patent/US20120157410A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8367672B2 (en) | 2004-11-02 | 2013-02-05 | Universite De Strasbourg | Pyridazine compounds, compositions and methods |
WO2011156901A2 (fr) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Composés, compositions et procédés pour traiter la sclérose en plaques |
WO2011156901A3 (fr) * | 2010-06-17 | 2012-02-02 | Waratah Pharmaceuticals Inc. | Composés, compositions et procédés pour traiter la sclérose en plaques |
Also Published As
Publication number | Publication date |
---|---|
WO2007127474A3 (fr) | 2008-06-19 |
US20120157410A1 (en) | 2012-06-21 |
WO2007127474A2 (fr) | 2007-11-08 |
US8158627B2 (en) | 2012-04-17 |
US20090197885A1 (en) | 2009-08-06 |
EP2015750A2 (fr) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158627B2 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
US9663493B2 (en) | Pyridazine compounds, compositions and methods | |
WO2007130383A2 (fr) | Compositions et traitements utilisant des pyridazines et des secrétases | |
US9408845B2 (en) | Formulations containing pyridazine compounds | |
WO2007127448A2 (fr) | Sels de composés de pyridazine | |
US8063047B2 (en) | Pyridazine compounds and methods | |
AU2012216322A1 (en) | Pyridazine compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20110427 |